Capital International Sarl Sells 42,797 Shares of Bristol Myers Squibb Company $BMY

Capital International Sarl lowered its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 26.5% in the 3rd quarter, HoldingsChannel reports. The firm owned 118,926 shares of the biopharmaceutical company’s stock after selling 42,797 shares during the quarter. Capital International Sarl’s holdings in Bristol Myers Squibb were worth $5,364,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Legal & General Group Plc boosted its stake in shares of Bristol Myers Squibb by 8.4% during the third quarter. Legal & General Group Plc now owns 17,075,743 shares of the biopharmaceutical company’s stock valued at $770,116,000 after purchasing an additional 1,317,199 shares in the last quarter. Banque Cantonale Vaudoise lifted its holdings in Bristol Myers Squibb by 26.0% during the third quarter. Banque Cantonale Vaudoise now owns 127,772 shares of the biopharmaceutical company’s stock worth $5,762,000 after buying an additional 26,347 shares during the period. Vestcor Inc boosted its position in Bristol Myers Squibb by 75.7% during the 3rd quarter. Vestcor Inc now owns 405,330 shares of the biopharmaceutical company’s stock valued at $18,280,000 after acquiring an additional 174,644 shares in the last quarter. Fieldview Capital Management LLC increased its holdings in shares of Bristol Myers Squibb by 375.3% in the 3rd quarter. Fieldview Capital Management LLC now owns 58,695 shares of the biopharmaceutical company’s stock valued at $2,647,000 after acquiring an additional 46,347 shares during the period. Finally, Russell Investments Group Ltd. raised its position in shares of Bristol Myers Squibb by 24.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,669,050 shares of the biopharmaceutical company’s stock worth $165,107,000 after acquiring an additional 728,381 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BMY. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $57.00 price objective (up from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Scotiabank reissued a “sector perform” rating and set a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a research report on Friday, January 9th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price objective for the company. Finally, BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $61.00.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase 3 SUCCESSOR-2 data — Oral mezigdomide combo improved progression-free survival in relapsed/refractory multiple myeloma, advancing BMY’s CELMoD program and de‑risking a high-value oncology asset. This is likely to broaden future revenue potential if regulatory paths proceed. Bristol Myers Squibb Announces Positive Phase 3 Results (BusinessWire)
• Positive Sentiment: FDA expands Sotyktu (TYK2 inhibitor) label to include psoriatic arthritis after strong POETYK data — adds a near-term commercial opportunity that can increase prescription volume and support top-line growth for the TYK2 franchise. BMY Wins FDA Nod to Expand Sotyktu Label (Zacks)
• Positive Sentiment: Pipeline update highlights TYK2 and CELMoD milestones — company commentary reinforced clinical momentum across multiple programs, which supports medium‑term growth expectations if approvals/commercial launches follow. Bristol Myers Squibb Pipeline Update (Yahoo Finance)
• Neutral Sentiment: Reuters and other outlets independently reported the same late‑stage oncology success, increasing media visibility but duplicating the primary clinical newsflow. This broad coverage can attract investor attention but may already be priced in. Bristol’s cancer treatment meets main goal (Reuters)
• Neutral Sentiment: Valuation/strategy pieces assess BMY’s revenue and earnings reset driven by the growth portfolio — useful for longer‑term investors but not immediate catalysts. Analysts’ models diverge on how quickly pipeline wins translate to consensus EPS. Assessing Bristol Myers Squibb Valuation (Yahoo Finance)
• Neutral Sentiment: Market commentary and stock‑interest articles (Zacks/Yahoo/MSN) have increased attention on BMY; trending interest can raise volatility but is not a directional fundamental change. Is Trending Stock Bristol Myers Squibb a Buy Now? (Yahoo/Zacks)
• Neutral Sentiment: Sector/market reports and portfolio reviews (Seeking Alpha, industry reports) referenced broader healthcare dynamics; these provide context but are not company‑specific catalysts. Virtus Large Cap Growth SMA Q4 2025 Portfolio Review (Seeking Alpha)
• Negative Sentiment: Analyst consensus remains a “Hold” — suggests analysts see upside risks balanced by execution or valuation concerns, which can cap upside near term and pressure the stock despite positive pipeline headlines. Bristol Myers Squibb Given Consensus Rating of “Hold” (American Banking News)

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $60.11 on Wednesday. The company has a 50 day moving average price of $57.90 and a 200 day moving average price of $51.20. The firm has a market capitalization of $122.41 billion, a P/E ratio of 17.42, a PEG ratio of 0.17 and a beta of 0.26. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same period in the prior year, the company posted $1.67 earnings per share. The firm’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.